Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept

Pallavi Tyagi; Zain Juma; Yong Keen Hor; Neil W. Scott; Andreea Ionean; Cynthia Santiago

doi:10.1186/s12886-018-0824-0

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept

Pallavi Tyagi^* (Corresponding Author), Zain Juma, Yong Keen Hor, Neil W. Scott, Andreea Ionean, Cynthia Santiago

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Background: To study the clinical outcomes of pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nAMD) in patients switched from Ranibizumab to Aflibercept. Methods: Retrospective non-comparative case series. 50 eyes with active nAMD and fovea involving PED of ≥100 μm measured manually using the caliper on the OCT, initially treated with intravitreal Ranibizumab (0.5 mg/0.05 ml) and later switched to Aflibercept (2.0 mg/0.05 ml). The outcome measures of best corrected visual acuity (BCVA), PED height, PED width and number of injections were measured at baseline and at time point of switch, 4 months, 1 year and at last follow up visit post-switch. Three paired t-tests and Pearson's correlations were calculated to analyze variables at switch and change in variables at 1 year. Results: After switch to Aflibercept, the improvement of BCVA was 1.84 (p = 0.11), 1.74 (p = 0.21) and 1.16 (p = 0.45) letters, the change in PED height was - 65.6μm (p < 0.001), - 50.64μm (p = 0.007) and - 68.48μm (p < 0.001) and the change in PED width was - 36.6μm (p = 0.514), + 29.7μm (p = 0.922) and + 118.4μm (p = 0.210) at 4 months, 1 year and the last visit respectively. There was a moderate negative correlation between reduction in PED height at 1 year after switch and PED height at the time of switch to Aflibercept (r = - 0.474, p < 0.05). Conclusion: The improvement in BCVA and change in PED width was not statistically significant however the reduction in PED height was significant after switching treatment to Aflibercept. The change in BCVA at 1 year after switch was not correlated with any of the analyzed anatomical characteristics of PED.

Original language	English
Article number	148
Number of pages	8
Journal	BMC Ophthalmology
Volume	18
DOIs	https://doi.org/10.1186/s12886-018-0824-0
Publication status	Published - 22 Jun 2018

Bibliographical note

PT received travel grant from BAYER, UK to attend international meetings
and AI and CS have received travel grants and speaker fees from Bayer and
Novartis, UK and acted as consultants for BAYER, UK

Data Availability Statement

The datasets generated and/or analysed during the current study are not
publicly available due as they’re part of larger data collection of age-related
macular degeneration treatment from electronic medical records but are
available from the corresponding author on reasonable request.

Keywords

Aflibercept
Neovascular age related macular degeneration
Pigment epithelial detachment

Access to Document

10.1186/s12886-018-0824-0Licence: CC BY

Tyagi_BMCO_Clinical_response_of_VOR
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated
Final published version, 827 KBLicence: CC BY

Cite this

@article{040e3f8289a44603a0bd587b951900f7,

title = "Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept",

abstract = "Background: To study the clinical outcomes of pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nAMD) in patients switched from Ranibizumab to Aflibercept. Methods: Retrospective non-comparative case series. 50 eyes with active nAMD and fovea involving PED of ≥100 μm measured manually using the caliper on the OCT, initially treated with intravitreal Ranibizumab (0.5 mg/0.05 ml) and later switched to Aflibercept (2.0 mg/0.05 ml). The outcome measures of best corrected visual acuity (BCVA), PED height, PED width and number of injections were measured at baseline and at time point of switch, 4 months, 1 year and at last follow up visit post-switch. Three paired t-tests and Pearson's correlations were calculated to analyze variables at switch and change in variables at 1 year. Results: After switch to Aflibercept, the improvement of BCVA was 1.84 (p = 0.11), 1.74 (p = 0.21) and 1.16 (p = 0.45) letters, the change in PED height was - 65.6μm (p < 0.001), - 50.64μm (p = 0.007) and - 68.48μm (p < 0.001) and the change in PED width was - 36.6μm (p = 0.514), + 29.7μm (p = 0.922) and + 118.4μm (p = 0.210) at 4 months, 1 year and the last visit respectively. There was a moderate negative correlation between reduction in PED height at 1 year after switch and PED height at the time of switch to Aflibercept (r = - 0.474, p < 0.05). Conclusion: The improvement in BCVA and change in PED width was not statistically significant however the reduction in PED height was significant after switching treatment to Aflibercept. The change in BCVA at 1 year after switch was not correlated with any of the analyzed anatomical characteristics of PED.",

keywords = "Aflibercept, Neovascular age related macular degeneration, Pigment epithelial detachment",

author = "Pallavi Tyagi and Zain Juma and Hor, {Yong Keen} and Scott, {Neil W.} and Andreea Ionean and Cynthia Santiago",

note = "PT received travel grant from BAYER, UK to attend international meetings and AI and CS have received travel grants and speaker fees from Bayer and Novartis, UK and acted as consultants for BAYER, UK",

year = "2018",

month = jun,

day = "22",

doi = "10.1186/s12886-018-0824-0",

language = "English",

volume = "18",

journal = "BMC Ophthalmology",

issn = "1471-2415",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept

AU - Tyagi, Pallavi

AU - Juma, Zain

AU - Hor, Yong Keen

AU - Scott, Neil W.

AU - Ionean, Andreea

AU - Santiago, Cynthia

N1 - PT received travel grant from BAYER, UK to attend international meetings and AI and CS have received travel grants and speaker fees from Bayer and Novartis, UK and acted as consultants for BAYER, UK

PY - 2018/6/22

Y1 - 2018/6/22

N2 - Background: To study the clinical outcomes of pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nAMD) in patients switched from Ranibizumab to Aflibercept. Methods: Retrospective non-comparative case series. 50 eyes with active nAMD and fovea involving PED of ≥100 μm measured manually using the caliper on the OCT, initially treated with intravitreal Ranibizumab (0.5 mg/0.05 ml) and later switched to Aflibercept (2.0 mg/0.05 ml). The outcome measures of best corrected visual acuity (BCVA), PED height, PED width and number of injections were measured at baseline and at time point of switch, 4 months, 1 year and at last follow up visit post-switch. Three paired t-tests and Pearson's correlations were calculated to analyze variables at switch and change in variables at 1 year. Results: After switch to Aflibercept, the improvement of BCVA was 1.84 (p = 0.11), 1.74 (p = 0.21) and 1.16 (p = 0.45) letters, the change in PED height was - 65.6μm (p < 0.001), - 50.64μm (p = 0.007) and - 68.48μm (p < 0.001) and the change in PED width was - 36.6μm (p = 0.514), + 29.7μm (p = 0.922) and + 118.4μm (p = 0.210) at 4 months, 1 year and the last visit respectively. There was a moderate negative correlation between reduction in PED height at 1 year after switch and PED height at the time of switch to Aflibercept (r = - 0.474, p < 0.05). Conclusion: The improvement in BCVA and change in PED width was not statistically significant however the reduction in PED height was significant after switching treatment to Aflibercept. The change in BCVA at 1 year after switch was not correlated with any of the analyzed anatomical characteristics of PED.

AB - Background: To study the clinical outcomes of pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nAMD) in patients switched from Ranibizumab to Aflibercept. Methods: Retrospective non-comparative case series. 50 eyes with active nAMD and fovea involving PED of ≥100 μm measured manually using the caliper on the OCT, initially treated with intravitreal Ranibizumab (0.5 mg/0.05 ml) and later switched to Aflibercept (2.0 mg/0.05 ml). The outcome measures of best corrected visual acuity (BCVA), PED height, PED width and number of injections were measured at baseline and at time point of switch, 4 months, 1 year and at last follow up visit post-switch. Three paired t-tests and Pearson's correlations were calculated to analyze variables at switch and change in variables at 1 year. Results: After switch to Aflibercept, the improvement of BCVA was 1.84 (p = 0.11), 1.74 (p = 0.21) and 1.16 (p = 0.45) letters, the change in PED height was - 65.6μm (p < 0.001), - 50.64μm (p = 0.007) and - 68.48μm (p < 0.001) and the change in PED width was - 36.6μm (p = 0.514), + 29.7μm (p = 0.922) and + 118.4μm (p = 0.210) at 4 months, 1 year and the last visit respectively. There was a moderate negative correlation between reduction in PED height at 1 year after switch and PED height at the time of switch to Aflibercept (r = - 0.474, p < 0.05). Conclusion: The improvement in BCVA and change in PED width was not statistically significant however the reduction in PED height was significant after switching treatment to Aflibercept. The change in BCVA at 1 year after switch was not correlated with any of the analyzed anatomical characteristics of PED.

KW - Aflibercept

KW - Neovascular age related macular degeneration

KW - Pigment epithelial detachment

UR - http://www.scopus.com/inward/record.url?scp=85048855906&partnerID=8YFLogxK

U2 - 10.1186/s12886-018-0824-0

DO - 10.1186/s12886-018-0824-0

M3 - Article

C2 - 29929478

AN - SCOPUS:85048855906

SN - 1471-2415

VL - 18

JO - BMC Ophthalmology

JF - BMC Ophthalmology

M1 - 148

ER -

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept

Abstract

Bibliographical note

Data Availability Statement

Keywords

Access to Document

Other files and links

Fingerprint

Cite this